Centaurus Financial Inc. Takes $1.08 Million Position in DexCom, Inc. $DXCM

Posted by Brenda Bartman on Aug 28th, 2026

Centaurus Financial Inc. purchased a new position in DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 15,971 shares of the medical device company’s stock, valued at approximately $1,076,000.

Other institutional investors have also made changes to their positions in the company. Reflection Asset Management acquired a new position in DexCom in the fourth quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the 1st quarter valued at about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $32,000. Wellington Grp LLC raised its position in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares during the period. Finally, DV Equities LLC bought a new position in DexCom during the 4th quarter worth approximately $36,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DXCM shares. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a report on Friday, May 1st. William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Wells Fargo & Company upped their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, BTIG Research reaffirmed a “buy” rating and set a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Get Our Latest Stock Analysis on DXCM

Insider Buying and Selling at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,035 shares of company stock worth $5,446,673 in the last three months. 0.28% of the stock is currently owned by company insiders.

DexCom Stock Up 0.4%

NASDAQ:DXCM opened at $89.29 on Friday. The stock has a 50-day simple moving average of $78.84 and a 200 day simple moving average of $71.47. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The company has a market cap of $33.69 billion, a PE ratio of 35.29, a PEG ratio of 1.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the prior year, the firm posted $0.48 EPS. The business’s revenue was up 13.1% on a year-over-year basis. On average, sell-side analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

DexCom Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.